Maxcyte (MXCT) Common Equity (2019 - 2026)

Maxcyte (MXCT) has 8 years of Common Equity data on file, last reported at $167.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $167.9 million, down 15.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $167.9 million (down 15.81% YoY), and the FY2025 annual result was $171.5 million, down 16.85% from the prior year.
• Common Equity retreated to $167.9 million in Q1 2026 per MXCT's latest filing, from $171.5 million in the prior quarter.
• Over five years, Common Equity peaked at $262.2 million in Q1 2022 and troughed at $167.9 million in Q1 2026.
• A 5-year average of $221.1 million and a median of $226.4 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 226.34% in 2022, then slipped 16.85% in 2025.
• A 5-year view of Common Equity shows it stood at $254.0 million in 2022, then dropped by 8.58% to $232.2 million in 2023, then fell by 11.16% to $206.3 million in 2024, then fell by 16.85% to $171.5 million in 2025, then retreated by 2.1% to $167.9 million in 2026.
• Business Quant data shows MXCT's Common Equity at $167.9 million in Q1 2026, $171.5 million in Q4 2025, and $180.3 million in Q3 2025.